BRAF and neoplasm: Considering this, constitutively active ERK mutation, but not other ERK mutations that affect ERK interaction with MEK1/2, phosphatases, or scaffolds, is probably not a feasible strategy for tumor cells to resist BRAF and MEK1/2 inhibition.